Wenze Tian1†
Shasha Zhang
Chao Jiang- 1Department of Thoracic Surgery, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, China
- 2General Surgery Department, Lianshui People’s Hospital Affiliated to Kangda College of Nanjing Medical University, Huai’an, Jiangsu, China
- 3Department of Thyroid and Breast Oncological Surgery, Huai’an Second People’s Hospital, The Affiliated Huaian Hospital of Xuzhou Medical University, Huai’an, Jiangsu, China
- 4Faculty of Life Science and Food Engineering, Huaiyin Institute of Technology, Huai’an, Jiangsu, China
- 5Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Engineering Research Center of Techniques and Instruments for Diagnosis and Treatment of Congenital Heart Disease, Institute of Developmental and Regenerative Medicine, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
- 6Department of Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, China
A Correction on
Myeloid Zinc Finger 1: insights into its oncogenic potential, prognostic value, and impact on immune microenvironment across cancers
By Tian W, Yu C, Xu X, Li J, Peng S, Sun A, Zhang S and Jiang C (2025). Front. Immunol. 16:1591912. doi: 10.3389/fimmu.2025.1591912
Author affiliation
In the article, there was an error in the affiliations. “Affiliation 3, Department of Thyroid and Breast Oncological Surgery, Huai’an Second People’s Hospital, The Affiliated Huaian Hospital of Xuzhou Medical University, Huai’an, Jiangsu, China”, was erroneously omitted for author “Aijun Sun”. This affiliation has now been added.
Additionally, author “Aijun Sun” was erroneously assigned to affiliation “2, General Surgery Department, Lianshui People’s Hospital Affiliated to Kangda College of Nanjing Medical University, Huai’an, Jiangsu, China”. This affiliation has now been removed.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Myeloid Zinc Finger 1, pan-cancer, tumor immunity, prognostic biomarker, immunotherapy drug susceptibility
Citation: Tian W, Yu C, Xu X, Li J, Peng S, Sun A, Zhang S and Jiang C (2025) Correction: Myeloid Zinc Finger 1: insights into its oncogenic potential, prognostic value, and impact on immune microenvironment across cancers. Front. Immunol. 16:1659836. doi: 10.3389/fimmu.2025.1659836
Received: 04 July 2025; Accepted: 07 July 2025;
Published: 25 July 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Tian, Yu, Xu, Li, Peng, Sun, Zhang and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Aijun Sun, c3VuYWlqdW4wOTE2QDE2My5jb20=; Shasha Zhang, emhhbmdzaGFzaGEzMDlAc2p0dS5lZHUuY24=; Chao Jiang, amlhbmdjaGFvMTIxMkAxMjYuY29t
†These authors have contributed equally to this work and share first authorship